MS: EMA Committee Supports Diroximel Fumarate Approval

MS: EMA Committee Supports Diroximel Fumarate Approval

European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has announced their approval of diroximel fumarate (Vumerity, Biogen Inc) for adults diagnosed with relapsing-remitting multiple sclerosis (MS). Although Diroximel fumarate is...